A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC | MicrobiomeTrials
A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC
RecruitingPHASE1, PHASE2INTERVENTIONAL
Trial Details
Start: 2025-12-05Est. Completion: 2028-07-10
Enrollment target: 123 participants
Locations
Rio Grande Urology, El Paso, Texas, United States
Utah Intermountain Medical Center, Murray, Utah, United States
Novartis Investigative Site, Malvern, Victoria, Australia
Novartis Investigative Site, Melbourne, Victoria, Australia
Novartis Investigative Site, Murdoch, Western Australia, Australia
Novartis Investigative Site, Bordeaux, France
Novartis Investigative Site, Clermont-Ferrand, France